Opinion
Video
Author(s):
Dr Amir H. Lebastchi delves into the latest advancements and evolving tactics in the field of prostate cancer biopsy and diagnostic procedures.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
Dr. Murphy on increasing diversity in cancer clinical trials
SBRT may offer a safe alternative to CFRT after prostatectomy
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic
Expert discusses the promise of emerging MISTs for BPH
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk